ArticleFrontiers in immunology2026
A mast cell-associated apoptosis-related transcriptomic signature in clear cell renal cell carcinoma and
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) exhibits substantial molecular and immune heterogeneity. Mast cells participate in tumor-microenvironment remodeling, but the prognostic relevance of mast cell-associated apoptosis-related transcriptional features remains unclear. Methods: Single-cell RNA sequencing was used to identify mast cells in ccRCC. Genes associated with the annotated mast-cell cluster were intersected with the HALLMARK_APOPTOSIS gene set to develop a mast cell-associated apoptosis score (MCAS) using machine-learning survival algorithms. MCAS was evaluated in TCGA-KIRC and two external cohorts. Associations with clinicopathological features, mutation profiles and model-derived genes were analyzed. YBX3 was functionally characterized using qRT-PCR, western blotting, CCK-8, colony formation, EdU, Transwell migration and flow cytometry assays. Results: A TPSAB1/CPA3-positive mast cell population was identified. The CoxBoost plus random survival forest model showed the best performance for MCAS construction. High MCAS scores predicted poor survival in the training and validation cohorts and were associated with advanced clinicopathological features and tumor mutation burden. SurvSHAP and SurvLIME jointly identified BNIP3, CX3CR1, HMOX1, and YBX3. High YBX3 expression was associated with unfavorable prognosis. Functionally, YBX3 knockdown inhibited proliferation, colony formation, DNA synthesis and migration, and promoted apoptosis with increased BAX and decreased Bcl-2, whereas YBX3 overexpression enhanced proliferative and migratory phenotypes. Conclusions: MCAS is a mast cell-associated apoptosis-related transcriptomic signature for prognostic stratification in ccRCC. The
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.